Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
Key facts
- Who runs it
- Northwestern University
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 1 May 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Treatments tested
- Dupilumab - Standard Dose
- Record updated
- 16 July 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Other criteria
- Well documented history of CRSwNP
- BSIT age/sex classified as "abnormal" score
- Self-reported stable olfactory deficit of moderate to severe quality > 3 months
- Prior endoscopic sinus surgery >3 months, <10 years prior
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Northwestern University Feinberg School of MedicineChicago, United StatesContact: Aditi Agarwal, MBBS, MSCITaking people
About the trial
What the trial wants to find out
The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are:
Read full original descriptionShow less
1. Does obstruction of the olfactory cleft predict return of the sense of smell? 2. Do electrophysiological signals generated by breathing and sniffing behavior predict return of the sense of smell?
Participants starting dupilumab will undergo assessment for their degree of olfactory cleft obstruction, and an electrophysiologic assessment of their olfactory cleft and be followed over 6 months of treatment with dupilumab.
The group in the trial
- Dupilumab Treatment
Patients who had prior endoscopic sinus surgery for CRSwNP with persistent smell loss initiating dupilumab
Treatment: Dupilumab - Standard Dose
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Olfactory Cleft Obstruction and Electrophysiological Olfactory Bulb Generated Beta Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
- Fit questions
- Built from NCT06892704, who can take part
- Record updated
- 16 July 2026